Dr. Wim Linssen

Neurologist

During studying medicine I wanted to graduate for either internal medicine or neurology. Becoming a neurologist, I’m still fascinated by clinically diagnosing neurological diseases on the basis of localising symptoms either due to central or to peripheral parts of the nervous system by combining  actual clinical complaints with the results of fysical neurological examination. I graduated PhD (1992) by studying some electrophysiological findings during muscle fatigue. I worked in the OLVG hospital in Amsterdam until 2020. I paticipated in OLVG   in good clinical care for neurological patients, in educating residents becoming a neurologist, in teaching students and in clinical research.

Specialty/areas of interest

Multiple sclerosis, neuromuscular disorders.

Languages

Dutch and English

Work experience

  • 1989: Registration as a neurologist, KU Nijmegen.
  • 1991- 2020: neurologist at OLVG, Amsterdam

Thesis: Electrophysiology of muscle fatigue.  A surface EMG study in normal skeletal muscle and in myopathy (1992).

Publications

Click here for Dr Linssen his publications

2010:   Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. Bolduc, G. Marlow, T.C. Conte, R. Lariviere, et al. Neuromuscular Disorders 2010;20(Issue 9):pp637.

2011:   Adverse events of Interferon Beta-1a: A prospective multi-centre international ICH-GCP-based CRO-supported external validation study in daily practice.  Jongen PJ, Sindic C, Sanders E, Hawkins S, Linssen W, van Munster E, Frequin F, Borm G and the international Functional Composite and Quality of life in Avonex-treated relapsing multiple sclerosis patients (FLAIR) study group.PloS One Medicine 2011;6:1-7.

2011:   Dysferlin and anoctamin 5 mutations in the Dutch distal muscular dystrophy cohort. 1. de Visser, W.H.J.P. Linssen, J.H.J. Wokke, R. Bernard, Lévy N, Ginjaar HB. Neuromuscular Disorders 2011;21, 9, pp 676

2012:   The ALS-FTD-Q: a new screening tool for behavioral disturbances in ALS.Raaphorst J, Beeldman E, Schmand B, Berkhout J, Linssen WHJP, van den Berg L, Pijnenburg YAL, Grupstra H, Weikamp J, Schelhaas HJ, Papma JM, van Swieten JC, de Visser M, De Haan RJ. Neurology 2012; 79:1377-83.

2012:   Selective pattern of muscle involvement seen in distal muscular dystrophy associated with anoctamin 5 mutations: A follow-up muscle MRI study. Mahjneh I, Bashir R, Kiuru-Enari S, Linssen W, Lamminen A, de Visser M. Neuromusc Dis 2012;22:130-6.

2012:   Tumefactive multiple sclerosis lesion under fingolimod treatment. Visser F, Wattjes MP, Pouwels PJW, Linssen WHJP, van Oosten BW. Neurology 2012;79:2000-3.

2013:   Long-term follow-up study on patients with Miyoshi phenotype of distal muscular dystrophy. Linssen WHJP, de Voogt W, Krahn M, Bernard R, Lévy N, Wokke JHJ,  Ginjaar HB, de Visser M. Eur J Neurol 2013;20:968-74.

2014:   Patient-reported adverse events of high-dose intravenous methylprednisolone for relapse treatment in multiple sclerosis (FEEL study). 1.Stavrakaki, E. Hoogervost, P. Pop, E. van Munster, W. Linssen , R. Hupperts. Sinnige, J. Kragt, W. Verhagen, L. Visser, R. van der Kruijk, H. Schrijver, J. Koeman, F. Verheul, W.Gladdines, F.Lonnqvist, P.J.Gaillard, P.J. Jongen  Multiple Sclerosis Journal 2014;20:201-2.

2014:   Severe weight loss and dropped head syndrome in MuSK myasthenia gravis.  Tan DYB, Linssen WHJP, Liberov BI. Case reports in clinical medicine 2014;3:587-591.

2014:   Comparing clinical data and muscle imaging of DYSF and ANO5 relatedmuscular dystrophies. ten Dam L, van der Kooi A, Rövekamp F, Linssen WHJP, de Visser M. Neuromuscul Dis 2014;12:1097-102.

2019:  Autosomal recessive limb-girdle and Miyoshi muscular dystrophies in the Netherlands: the clinical and molecular spectrum of 244 patients. Ten Dam L, Frankhuizen WS, Linssen WH, Straathof CS,  Niks EH, Faber CG, Fock JM, Kuks J, Brusse E, de Coo IF, Voermans N, Verrips A , Hoogendijk JE, Van der Pol L, Westra D, De Visser M, Van der Kooi AM, Ginjaar HB. Clinical Genetics 2019:1-8.

2020:   Second intravenous immunoglobulin Dose in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): a double-blind, randomized, placebo-controlled, clinical trial C Walgaard, BC Jacobs,  HF Lingsma, EW Steyerberg, B van den Berg, AY Doets, SE Leonhard, JC Verboon, HG Huizinga, J Drenthen, S Arends, RP Kleyweg, K Kuitwaard, MFG van der Meulen, JPA Samijn, FH Vermeij, JBM Kuks, GW van Dijk, PW Wirtz, F Eftimov,  AJ van der Kooi, MPJ Garssen, CJ Gijsbers, MC de Rijk, LH Visser, RJ Blom, WHJP Linssen, E.. van der Kooi, JJGM Verschuuren, R van Koningsveld, HJG Dieks, HJ Gilhuis, K Jellema, TC van der Ree, HME Bienfait, CG Faber, H Lovenich, BGM van Engelen, RJ Groen, ISJ Merkies, BW van Oosten, WL van der Pol, WDM van der Meulen, UA Badrising, M Stevens,  AJ Breukelman, CP  Zwetsloot, MM van der Graaff, RJO van der Ploeg, M Wohlgemuth, RAC Hughes, DR Cornblath, and PA van Doorn, on behalf of the Dutch GBS Study Group.

Lancet Neurology, accepted for publication 2020.